http://rdf.ncbi.nlm.nih.gov/pubchem/patent/HU-0001528-A2
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-64 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-472 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-64 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-403 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-427 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4965 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-42 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4439 |
| filingDate | 1997-12-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a5210f92aa9d1dc60a4b754f0ddca550 |
| publicationDate | 2000-11-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | HU-0001528-A2 |
| titleOfInvention | Synergistic combination of sulfonylurea and glitazone for the treatment of diabetes |
| abstract | The present invention relates to a combination of anti-diabetic sulfonylurea compounds and glitazone compounds, and to the use of such combinations in the treatment of diabetes. Type II diabetes, in addition to insulin resistance, is mainly signaled by a diminished pancreatic response to the glucose stimulus. Improving insulin resistance by administering a single glitazone compound has the great advantage of being combined with a single-step therapy for stimulating insulin release (e.g., sulfonylurea). Glitazone and sulfonylurea combination therapy appears to be safe and well-reversible and may result in significant and synergistic improvements in glycemic control. Patients treated with maximum doses of sulphonylureas should not be switched to glitazone monotherapy. Monotherapy, if indicated, should only be achieved by down-titration of the dose of the sulphonylurea. The application of the test results should not be limited to patients whose maximal dose of sulfonylurea is ineffective, but may be extended to patients treated with lower doses of sulfonylurea. SHE |
| priorityDate | 1997-02-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 165.